Biosimilar Antibodies

Sonesitatug is a humanized IgG1κ monoclonal antibody that specifically targets CLDN18. For experimental rigor, it is recommended to use Human IgG1 kappa as an isotype control.

Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody specifically targeting matrix metalloproteinase 9 (MMP9). Demonstrating antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models, Andecaliximab is suitable for research applications focused on gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF). This antibody offers a valuable tool for investigating the role of MMP9 in tissue remodeling and fibrosis.

Ormutivimab (rhRIG) is a recombinant human monoclonal antibody specifically designed to target the rabies virus. This antibody demonstrates broad neutralizing activity against multiple strains of the rabies virus, making it a critical tool in post-exposure prophylaxis (PEP) models. Ormutivimab's high efficacy in neutralizing rabies virus highlights its potential as a therapeutic option in managing exposures to this lethal virus.

Ibritumomab is a murine-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD20 (MS4A1). This antibody is engineered with a human IgG1 heavy chain and a human kappa light chain, resulting in a predicted molecular weight of 145 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended.

Belrestotug (EOS-448) is a human immunoglobulin G1 kappa (hIgG1 kappa) antibody that acts as an antagonist to TIGIT (VSIG9, VSTM3). This monoclonal antibody exhibits antineoplastic activity, targeting and modulating immune responses that are critical in the context of oncology research. Belrestotug is designed for the study of immune checkpoint pathways and their role in cancer immunotherapy.

The Anti-MERS-2E6 monoclonal antibody (MERS-2E6; MERS Antibody-2E6) is a human IgG1 isotype, expressed in CHO cells, designed to neutralize Middle East Respiratory Syndrome coronavirus (MERS-CoV). This antibody competitively inhibits the binding of the viral spike protein to its cellular receptor, CD26 (DPP4), effectively blocking the virus from entering host cells. This mechanism positions the Anti-MERS-2E6 mAb as a critical tool for research into viral pathogenesis and the development of therapeutic strategies against MERS-CoV.

Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3, designed for the study of metastatic castration-resistant prostate cancer (mCRPC). This antibody exhibits binding affinities with dissociation constants (K_D) of 9.4 nM for human CD3 and 47.0 nM for PSMA, facilitating its dual specificity. Pasotuxizumab is instrumental in engaging T-cells and directing them towards PSMA-expressing prostate cancer cells, making it a valuable tool for advanced prostate cancer research.

The Anti-CXCL4/PF4 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CXCL4/PF4 protein. This antibody comprises a human IgG4SP type heavy chain and a human kappa type light chain, with an estimated molecular weight of 144.5 kDa. For experimental control purposes, the Human IgG4 kappa Isotype Control is recommended. This antibody is ideal for research applications focusing on the biological roles and regulatory mechanisms of the CXCL4/PF4 chemokine in inflammation and coagulation processes.

Trevogrumab (REGN-1033) is a monoclonal antibody that specifically targets growth differentiation factor 8 (GDF8), also known as myostatin. This antibody is utilized in scientific studies focused on muscle wasting conditions such as disuse atrophy, chronic diseases, and alterations in dietary and nutrient intake. Trevogrumab is instrumental in elucidating the pathways and molecular mechanisms underlying muscle degeneration and recovery, making it a valuable tool in muscle biology research.

TAK-701 is a humanized monoclonal antibody that targets human hepatocyte growth factor (HGF), exhibiting potential antineoplastic properties. This antibody is specifically designed to bind to HGF, a multifunctional cytokine involved in cell growth, motility, and morphogenesis of various tissues, with a particular focus on its role in tumorogenesis. TAK-701 has shown efficacy in reversing gefitinib resistance in non-small-cell lung cancer (NSCLC), suggesting its utility in enhancing response rates to conventional therapies in resistant cancer cells. This makes it a valuable tool for research in cancer treatment modalities, particularly in understanding and overcoming drug resistance mechanisms in NSCLC.

Mecbotamab is a humanized IgG1-κ monoclonal antibody specifically designed to target the AXL receptor tyrosine kinase (AXL). This antibody functions as a conditionally active biologic (CAB), allowing for site-specific activation. Mecbotamab can be conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) through a cleavable linker, creating the antibody-drug conjugate (ADC) known as Mecbotamab vedotin (BA3011). This conjugation enhances its potential for targeted cancer therapy by enabling the selective delivery of the cytotoxic drug to AXL-expressing tumor cells, thereby minimizing systemic toxicity.

The Anti-GPR20 Antibody (DS-6157) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the GPR20 receptor, a G protein-coupled receptor implicated in various physiological processes. This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, exhibiting a predicted molecular weight of approximately 150 kDa. For experimental controls, the Human IgG1 kappa Isotype Control is recommended as a suitable reference.